Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more aggressive Sezary syndrome (SS). Oncogenic microRNAs (miRs) are stable epigenetic inhibitors often deregulated in the tumour and detectable as biomarkers in non-cellular fractions of peripheral blood. The tumour-specific expression of miR-155, miR-203, and miR-205 was shown to correctly diagnose CTCL. We herein asked whether these microRNAs can be used as plasma biomarkers for clinical CTCL monitoring. Patients with CTCL (n = 10) and controls with non-malignant conditions (n = 11) repeatedly donated plasma samples every ca. five months. MicroRNAs were detected in the plasma samples by specifically-primed RT-PCR followed by multivariate analyses of the miR expression dynamics. We herein established the plasma miR-classifier for detecting CTCL based on the miR-155 upregulation and miR-203/miR-205 downregulation with 100% specificity and 94% sensitivity. The 3-miR-score in the consecutive samples coincided with the clinical outcome of MF and SS patients such as the therapy response or changes in the clinical stage or tumor size. Quantitation of the selected microRNAs in plasma is a specific and straightforward approach for evaluating CTCL outcome representing, thus, a valuable tool for CTCL diagnostics and therapy response monitoring.

BIOCEV 1st Faculty of Medicine Charles University 25250 Vestec Czech Republic

Department of Dermatology and Venereology 1st Faculty of Medicine Charles University and General Hospital 12808 Prague Czech Republic

Department of Haematology 1st Faculty of Medicine Charles University and General Hospital 12808 Prague Czech Republic

Faculty of Mathematics and Physics Charles University 18675 Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University 12853 Prague Czech Republic

See more in PubMed

Wilcox R.A. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2016;91:151–165. doi: 10.1002/ajh.24233. PubMed DOI PMC

Mirvish J.J., Pomerantz R.G., Falo L.D., Jr., Geskin L.J. Role of infectious agents in cutaneous T-cell lymphoma: Facts and controversies. Clin. Dermatol. 2013;31:423–431. doi: 10.1016/j.clindermatol.2013.01.009. PubMed DOI

Ballegaard V., Ralfkiaer U., Pedersen K.K., Hove M., Koplev S., Braendstrup P., Ryder L.P., Madsen H.O., Gerstoft J., Gronbaek K., et al. MicroRNA-210, MicroRNA-331, and MicroRNA-7 are differentially regulated in treated HIV-1-infected individuals and are associated with markers of systemic inflammation. JAIDS. 2017;74:e104–e113. doi: 10.1097/QAI.0000000000001191. PubMed DOI

Van der Fits L., van Kester M.S., Qin Y., Out-Luiting J.J., Smit F., Zoutman W.H., Willemze R., Tensen C.P., Vermeer M.H. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J. Investig. Dermatol. 2011;131:762–768. doi: 10.1038/jid.2010.349. PubMed DOI

Ralfkiaer U., Hagedorn P.H., Bangsgaard N., Lovendorf M.B., Ahler C.B., Svensson L., Kopp K.L., Vennegaard M.T., Lauenborg B., Zibert J.R., et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL) Blood. 2011;118:5891–5900. doi: 10.1182/blood-2011-06-358382. PubMed DOI PMC

Sochor M., Basova P., Pesta M., Dusilkova N., Bartos J., Burda P., Pospisil V., Stopka T. Oncogenic microRNAs: MiR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014;14:448. doi: 10.1186/1471-2407-14-448. PubMed DOI PMC

Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., Zackheim H., Duvic M., Estrach T., Lamberg S., et al. Iscl/Eortc, Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood. 2007;110:1713–1722. PubMed

Marstrand T., Ahler C.B., Ralfkiaer U., Clemmensen A., Kopp K.L., Sibbesen N.A., Krejsgaard T., Litman T., Wasik M.A., Bonefeld C.M. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk. Lymphoma. 2014;55:957–958. doi: 10.3109/10428194.2013.815352. PubMed DOI

Ralfkiaer U., Lindahl L.M., Litman T., Gjerdrum L.M., Ahler C.B., Gniadecki R., Marstrand T., Fredholm S., Iversen L., Wasik M.A., et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014;34:7207–7217. PubMed

Ning M.S., Andl T. Custodians of the transcriptome: How microRNAs guard stemness in squamous epithelia. Stem Cells. 2015;33:1047–1054. doi: 10.1002/stem.1922. PubMed DOI PMC

Chim C.S., Wong K.Y., Leung C.Y., Chung L.P., Hui P.K., Chan S.Y., Yu L. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J. Cell. Mol. Med. 2011;15:2760–2767. doi: 10.1111/j.1582-4934.2011.01274.x. PubMed DOI PMC

Vargova K., Curik N., Burda P., Basova P., Kulvait V., Pospisil V., Savvulidi F., Kokavec J., Necas E., Berkova A., et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117:3816–3825. doi: 10.1182/blood-2010-05-285064. PubMed DOI

Huskova H., Korecka K., Karban J., Vargova J., Vargova K., Dusilkova N., Trneny M., Stopka T. Oncogenic microRNA-155 and its target PU.1: An integrative gene expression study in six of the most prevalent lymphomas. Int. J. Hematol. 2015;102:441–450. doi: 10.1007/s12185-015-1847-4. PubMed DOI

Kopp K.L., Ralfkiaer U., Gjerdrum L.M., Helvad R., Pedersen I.H., Litman T., Jonson L., Hagedorn P.H., Krejsgaard T., Gniadecki R. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013;12:1939–1947. doi: 10.4161/cc.24987. PubMed DOI PMC

Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., Croce C.M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA. 2006;103:7024–7029. doi: 10.1073/pnas.0602266103. PubMed DOI PMC

Kopp K.L., Ralfkiaer U., Nielsen B.S., Gniadecki R., Woetmann A., Odum N., Ralfkiaer E. Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma. APMIS. 2013;121:1020–1024. doi: 10.1111/apm.12162. PubMed DOI

Krejsgaard T., Lindahl L.M., Mongan N.P., Wasik M.A., Litvinov I.V., Iversen L., Langhoff E., Woetmann A., Odum N. Malignant inflammation in cutaneous T-cell lymphoma—A hostile takeover. Semin. Immunopathol. 2017;39:269–282. doi: 10.1007/s00281-016-0594-9. PubMed DOI PMC

Moyal L., Barzilai A., Gorovitz B., Hirshberg A., Amariglio N., Jacob-Hirsch J., Maron L., Feinmesser M., Hodak E. MiR-155 is involved in tumor progression of mycosis fungoides. Exp. Dermatol. 2013;22:431–433. doi: 10.1111/exd.12161. PubMed DOI

McGirt L.Y., Adams C.M., Baerenwald D.A., Zwerner J.P., Zic J.A., Eischen C.M. MiR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J. Investig. Dermatol. 2014;134:1101–1107. doi: 10.1038/jid.2013.461. PubMed DOI PMC

Sibbesen N.A., Kopp K.L., Litvinov I.V., Jonson L., Willerslev-Olsen A., Fredholm S., Petersen D.L., Nastasi C., Krejsgaard T., Lindahl L.M., et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget. 2015;6:20555–20569. doi: 10.18632/oncotarget.4111. PubMed DOI PMC